利妥昔单抗联合Hyper-CVAD治疗套细胞淋巴瘤临床分析

Rituximab combined with Hyper-CVAD for mantle cell lymphoma

目的观察利妥昔单抗联合Hyper CVAD化疗方案治疗套细胞淋巴瘤的临床疗效。方法将32例初治套细胞淋巴瘤患者分2组:对照组常规给予Hyper CVAD方案,治疗组在对照组治疗的基础上,加用利妥昔单抗。观察两组近期有效率和相关不良反应。结果对照组总有效率58.8%,CR 5例;治疗组的总有效率为80.0%,CR 8例。主要不良反应为骨髓抑制,其次是消化道反应。不良反应在两组之间无显著性差异。结论在套细胞淋巴瘤的治疗中R-hyper CVAD方案疗效优于hyper CVAD方案。

【Objective】This study was to evaluate the safety and efficacy of modified Rituximab（R） combined with Hyper-CVAD regimen in Chinese patients with MCL.【Methods】32 patients pathologically diagnosed as MCL who did not receive treatment before,were assigned to two groups.Control group（n =17） and Treatment group（n =15）.The patients in the two groups received 4 cycles of Hyper CVAD regime or R-Hyper CVAD regime.The adverse reaction,short-term response was evaluated.【Results】In Control group： CR（5cases）,The overall response rate（RR） was 58.8%.In Treatment group： CR（8 cases）,RR was 80.0%.The main toxicities in two groups were myelosuppression and digestive toxicity.There was no significant difference in toxicities between the two groups.【Conclusion】 Modified R-Hyper CVAD regimen is a promising regimen for the patients with MCL.